GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...

The FTSE 100 index has started the year well as it surged to a record high. It moved to a high of £8,645, up by over 75% from ...

Geneos Wealth Management Inc. purchased a new stake in shares of GSK plc (NYSE:GSK – Free Report) during the fourth quarter, ...

Two innovative projects in Nigeria and Ethiopia have received significant funding from Save the Children through its Immunisation Accelerator, supported by ...

The 30th Nigerian Economic Summit (#NES30) was held in Abuja on October 14, 2024. At that summit, the Vice President of the ...

What we know after American Airlines plane crashes with Black Hawk helicopter in Washington, D.C. Queens of Rock: 25 Legendary Women Who Changed the Music Industry Forever!

Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

Pharmaceutical giant GSK and the University of Oxford are collaborating on developing a cancer vaccine that aims to detect pre-cancer cells up to 20 y ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Dr. Blackman brings his singular experience as co-founder of Day One Biopharmaceuticals and a physician-scientist in pediatric neuro-oncology to the PBTF's pediatric brain tumor community BOSTON, Jan.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.